a Department of Physiology and Pharmacology , Karolinska Institutet , Stockholm , Sweden.
b SENSORION SA , Montpellier , France.
Expert Opin Emerg Drugs. 2018 Dec;23(4):251-260. doi: 10.1080/14728214.2018.1555240. Epub 2018 Dec 7.
: During the last decade, a number of candidate drugs for the treatment of tinnitus have emerged with the hope of alleviating the burden of millions of sufferers with a persisting ringing in their ears. Knowledge of the pathophysiologic mechanisms has progressed remarkably in the recent years, which has led to the identification of potential new drug targets for the treatment of tinnitus. However, pharmacologic interventions are still limited. : In this editorial results from recent Phase 3 and Phase 2a trials investigating the NMDA receptor antagonist AM-101 from Auris Medical, the AMPA receptor antagonist BGG492 from Novartis and the Kv3 modulator AUT00063 from Autifony Therapeutics will be discussed. In this context, we will reevaluate the translational development approach from animal models to clinical trials and seize this opportunity to debate and improve future R&D in tinnitus pipeline. : In spite of huge advances in pathophysiologic knowledge and research methodology in the last decades, pharmaceutical research in tinnitus still represents a high-risk field. Important research directions include the identification of potential therapeutic targets and the development of objective outcome measurements to facilitate translational research.
在过去的十年中，出现了许多治疗耳鸣的候选药物，希望能减轻数以百万计的持续性耳鸣患者的负担。近年来，对病理生理机制的认识有了显著进展，这为治疗耳鸣的潜在新药靶点的确定提供了可能。然而，药物干预仍然有限。 在这篇社论中，我们将讨论 Auris Medical 的 NMDA 受体拮抗剂 AM-101、诺华的 AMPA 受体拮抗剂 BGG492 和 Autifony Therapeutics 的 Kv3 调节剂 AUT00063 的最近 3 期和 2a 期试验结果。在这方面，我们将重新评估从动物模型到临床试验的转化开发方法，并抓住这个机会讨论和改进耳鸣管道的未来研发。 尽管在过去几十年中，病理生理学知识和研究方法取得了巨大进展，但耳鸣的药物研究仍然是一个高风险领域。重要的研究方向包括确定潜在的治疗靶点和开发客观的疗效测量方法，以促进转化研究。
